

MEETING NOTICE

ANNUAL GENERAL COMBINED MEETING OF THE SHAREHOLDERS

OF 28 APRIL 2021, 5PM CET

Agenda for the Ordinary General Meeting

- management report of the Executive Board including the report on the Group - report of the Supervisory Board - presentation by the Executive Board of the annual and consolidated financial statements for the year ended 31 December 2020,
 - statutory auditors' report on the corporate accounts for the year ended 31 December 2020, on corporate governance and on the agreements referred to in Articles L. 225-86 et seq. of the French Commercial Code,
 - statutory auditors' report on the consolidated financial statements for the year ended 31 December 2020,
1. approval of the corporate accounts for the year ended 31 December 2020,
 2. approval of the consolidated financial statements for the year ended 31 December 2020,
 3. allocation of results for the year ended 31 December 2020,
 4. review of the agreements referred to in Articles L. 225-86 et seq. of the French Commercial Code,
 5. approval of the elements of remuneration due or awarded for the 2020 financial year to the Chairman of the Executive Board, Mr Laurent Levy,
 6. approval of the elements of remuneration due or awarded for the 2020 financial year to Ms Anne-Juliette Hermant, for her term of office as a member of the Executive Board and her employment contract,
 7. approval of the elements of remuneration due or awarded for the 2020 financial year to Mr Philippe Mauberna for his term of office as member of the Executive Board and his employment contract,
 8. approval of the elements of remuneration due or awarded for the 2020 financial year to Mr Laurent Condomine for his term of office as Chairman of the Supervisory Board,
 9. vote on information relating to remuneration for board members in 2020 (excluding board directors) mentioned in Article L. 22-10-9 of the French Commercial Code,
 10. approval of the Supervisory Board member remuneration policy for the 2021 financial year,
 11. approval of Mr Laurent Levy's remuneration policy for his term of office as Chairman of the Executive Board for the 2021 financial year,
 12. approval of Ms Anne-Juliette Hermant's remuneration policy for her term of office as member of the Executive Board and for her employment contract for the 2021 financial year,
 13. approval of Mr Philippe Mauberna's remuneration policy for his term of office as member of the Executive Board and his employment contract for the 2021 financial year,
 14. approval of the 2020 Stock Option Plan adopted by the Executive Board during its meeting on 9 January 2021,
 15. authorisation to be given to the Executive Board for the Company's purchase of its own shares.

Agenda for the Extraordinary General Meeting

16. authorisation to be given to the Executive Board to reduce the share capital through the cancellation of shares within the framework of the authorisation to buy back its own shares,

17. delegation of authority to be granted to the Executive Board to increase the capital by issuing ordinary shares and/or any transferable securities, while maintaining preferential subscription rights,
18. delegation of authority to be granted to the Executive Board to increase the capital by issuing ordinary shares and/or any transferable securities, with cancellation of the shareholders' preferential subscription rights by way of public offering (outside of offers referred to in paragraph 1 of Article L. 411-2 of the French Financial and Monetary Code),
19. delegation of authority to be granted to the Executive Board to increase the capital by issuing ordinary shares and/or any transferable securities, with cancellation of the shareholders' preferential subscription rights, within the framework of an offer referred to in paragraph 1 of Article L. 411-2 of the French Financial and Monetary Code,
20. authorisation to be granted to the Executive Board, in the event of the issuing of shares and/or any transferable securities granting access to the capital with cancellation of the shareholders' preferential subscription rights by virtue of the above-mentioned delegations, for the purpose of setting the issue price within the limit of 10% of the share capital,
21. delegation of authority to be granted to the Executive Board to increase the capital immediately or at a later date by issuing ordinary shares and/or securities, with cancellation of the shareholders' preferential subscription rights to the benefit of a category of persons meeting characteristics specified in the context of the implementation of an equity or bond financing agreement,
22. delegation of authority to be granted to the Executive Board to increase the capital by issuing ordinary shares and/or any transferable securities, with cancellation of the shareholders' preferential subscription rights to the benefit of categories of persons meeting specific characteristics (investors with experience in the health or biotechnology sector; credit institutions, investment services providers or a member of an investment syndicate guaranteeing the completion of the issue in question);
23. delegation of authority to be granted to the Executive Board to increase the capital by issuing ordinary shares and/or any transferable securities, with cancellation of the shareholders' preferential subscription rights to the benefit of a category of persons meeting specific characteristics (industrial companies, institutions or entities active in the health or biotechnology sector);
24. delegation of authority to be granted to the Executive Board to increase the number of securities to be issued in the event of a capital increase with or without preferential subscription right decided under the above-mentioned delegations,
25. delegation of authority to be granted to the Executive Board for the purpose of issuing ordinary shares and transferable securities granting access to the Company's capital, in the event of a public offering with an exchange component initiated by the Company,
26. delegation of authority to be granted to the Executive Board to increase the share capital, within the limit of 10% of the capital, to compensate for contributions in kind of equity or equity-linked securities of external companies outside of a public exchange offer,
27. setting of the overall limitations of the amount of issues made under the above-mentioned delegations,
28. delegation of authority to be granted to the Executive Board to increase capital by incorporation of premiums, reserves, profits or other,
29. authorisation to be given to the Executive Board to grant Company share subscription or purchase options in accordance with the provisions of Articles L. 225-177 et seq. of the French Commercial Code, leading to the shareholders' waiver of their preferential subscription right,
30. authorisation to be given to the Executive Board to proceed with the free allocation of existing shares or shares to be issued, in accordance with the provisions of Articles L. 225-197-1 et seq. of the French Commercial Code, leading to the shareholders' waiver of their preferential subscription right,

31. delegation of authority to be granted to the Executive Board for the purpose of issuing and allocating share subscription warrants with cancellation of the shareholders' preferential subscription rights to the benefit of a category of persons meeting determined characteristics,
32. setting of the overall limitations of the amount of issues that may be made under the authorisations to be granted for the purpose of granting share subscription or purchase options and to proceed with the free allocation of shares and delegation for the purpose of issuing the above-mentioned share subscription warrants,
33. amendment of the age limit applicable to members of the Supervisory Board – amendments in correlation with the Articles of Association,
34. amendment of Article 22 “Shareholders’ General Meetings”,
35. delegation to be granted to the Executive Board to increase the share capital by issuing shares and transferable securities giving access to the Company’s capital for employees adhering to the Group Savings Plan.

Agenda for the Ordinary General Meeting

36. approval of the Supervisory Board member remuneration policy